AI Stock Analysis - Biomea Fusion (BMEA)
Analysis generated September 1, 2025.
Biomea Fusion is a company nested within the healthcare sector, primarily focused on the development and promotion of innovative therapeutic solutions. Specializing in precision oncology, Biomea Fusion aims to provide ground-breaking treatments for serious diseases with unmet medical needs. Their focus on delivering value through advanced biotechnological methods positions them as a potential leader in the industry.
Stock Alerts - Biomea Fusion (BMEA)
 |
Biomea Fusion | February 6 Price is up by 6.1% in the last 24h. |
|
Biomea Fusion | February 5 Price is up by 6.4% in the last 24h. |
|
Biomea Fusion | February 4 Price is down by -6.3% in the last 24h. |
|
Biomea Fusion | February 2 Price is down by -7.1% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Biomea Fusion
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 1 | Sign up | Sign up | Sign up |
| Sentiment | 83 | Sign up | Sign up | Sign up |
| Webpage traffic | 10,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | N/A | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 1,527 | Sign up | Sign up | Sign up |
| Instagram Followers | 4,650 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 76 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 2,266 | Sign up | Sign up | Sign up |
| X Followers | 3,465 | Sign up | Sign up | Sign up |
| X Mentions | 10 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 154 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 71 | Sign up | Sign up | Sign up |
| Linkedin Employees | 69 | Sign up | Sign up | Sign up |
About Biomea Fusion
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases.
| Price | $1.22 |
| Target Price | Sign up |
| Volume | 1,190,000 |
| Market Cap | $86M |
| Year Range | $0.96 - $2.9 |
| Dividend Yield | 0% |
| Analyst Rating | 75% buy |
| Industry | Biotechnology |
In the news
Rodman & Renshaw Initiates Biomea Fusion (BMEA) at Buy with $8 Price TargetJanuary 19 - Yahoo Entertainment |
|
 |
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference - SlideshowJanuary 15 - SeekingAlpha |
Biomea Fusion, Inc. (BMEA) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptJanuary 14 - SeekingAlpha |
|
 |
Biomea Fusion initiated with bullish view at Rodman & RenshawJanuary 13 - Thefly.com |
 |
Biomea Fusion enters 2026 focused on icovamenib, BMF-650 milestonesJanuary 12 - Thefly.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 0 | 0 | 0 | -16M | -16M | -0.270 |
| Q2 '25 | 0 | 500,000 | -500,000 | -21M | -20M | -0.510 |
| Q1 '25 | 0 | 0 | 0 | -29M | -29M | -0.800 |
| Q4 '24 | 1.2M | 0 | 1.2M | -29M | -30M | -0.810 |
| Q3 '24 | 0 | 400,000 | -400,000 | -33M | -34M | -0.910 |
Insider Transactions View All
| Erdtmann Rainer M filed to buy 723,027 shares at $1.4. December 15 '25 |
| Hitchcock Michael J.M. filed to buy 115,000 shares at $1. December 4 '25 |
| Erdtmann Rainer M filed to buy 693,027 shares at $1.1. December 2 '25 |
| Erdtmann Rainer M filed to buy 683,027 shares at $1.1. December 2 '25 |
| Hitchcock Michael J.M. filed to buy 15,000 shares at $10.1. October 1 '24 |
Similar companies
Read more about Biomea Fusion (BMEA) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
FAQ - Biomea Fusion
The Market Cap of Biomea Fusion is $86M.
Currently, the price of one share of Biomea Fusion stock is $1.22.
The BMEA stock price chart above provides a comprehensive visual representation of Biomea Fusion's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Biomea Fusion shares. Our platform offers an up-to-date BMEA stock price chart, along with technical data analysis and alternative data insights.
As of our latest update, Biomea Fusion (BMEA) does not offer dividends to its shareholders. Investors interested in Biomea Fusion should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
Some of the similar stocks of Biomea Fusion are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
